2
Participants
Start Date
March 31, 2016
Primary Completion Date
May 10, 2016
Study Completion Date
May 10, 2016
Enzalutamide
Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
Niraparib
Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
Tufts Medical Center, Boston
Collaborators (1)
Hoosier Cancer Research Network
OTHER
Tesaro, Inc.
INDUSTRY
Paul Mathew, MD
OTHER